Sprifermin (AS902330) 10 mcg + Sprifermin (AS902330) 30 mcg + Sprifermin (AS902330) 100 mcg
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Isolated Cartilage Injury of the Knee
Conditions
Isolated Cartilage Injury of the Knee
Trial Timeline
Mar 1, 2010 → Apr 1, 2013
NCT ID
NCT01066871About Sprifermin (AS902330) 10 mcg + Sprifermin (AS902330) 30 mcg + Sprifermin (AS902330) 100 mcg
Sprifermin (AS902330) 10 mcg + Sprifermin (AS902330) 30 mcg + Sprifermin (AS902330) 100 mcg is a phase 2 stage product being developed by Merck for Isolated Cartilage Injury of the Knee. The current trial status is terminated. This product is registered under clinical trial identifier NCT01066871. Target conditions include Isolated Cartilage Injury of the Knee.
What happened to similar drugs?
0 of 2 similar drugs in Isolated Cartilage Injury of the Knee were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01066871 | Phase 2 | Terminated |
Competing Products
4 competing products in Isolated Cartilage Injury of the Knee
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olmesartan medoxomil + hydrochlorothiazide, if necessary + nitrendipine + hydrochlorothiazide, if necessary | Daiichi Sankyo | Phase 3 | 40 |
| Rebif® | Merck | Phase 3 | 40 |
| romiplostim | Amgen | Phase 2 | 35 |
| 6R-BH4 | BioMarin Pharmaceutical | Phase 2 | 24 |